More than a year after Johnson & Johnson and Bayer pulled the plug on an open-label study for anticoagulant Xarelto in patients after a rare valve replacement procedure, the drugmaker is still grasping at straws for what exactly happened. More:
read moreIt’s been just a few weeks since Novartis’ Entresto flopped a crucial heart failure study in what the drugmaker called a “narrow miss.” Now, subanalyses from multiple studies show Entresto had a “profound effect” on some patients, giving Novartis hope for a second
read moreAnother candidate for Novartis’ future blockbuster club is here. Now armed with an early FDA approval for Adakveo, the Swiss drugmaker will launch the first targeted therapy to prevent painful vaso-occlusive crises in sickle cell disease patients. More: Novartis eyes
read moreTurns out AstraZeneca’s “paradigm shifting” outcomes data for SLGT2 med Farxiga show an even greater cardiovascular benefit for patients who don’t have diabetes than those who do—and this for a drug designed specifically to treat the disease. More: AHA: AstraZeneca's Farxiga outcomes data looks even
read more© 1994 - 2026 B.M. Pharmaceuticals